Development of the treatment that targeted an arachidonate cascade of the oral cancer neighborhood environment

Research Project

Project/Area Number	24593022
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Surgical dentistry
Research Institution	Hokkaido University
Principal Investigator	KOBORI YOSHINORI 北海道大学, 大学病院, 助教 (70374551)
Co-Investigator(Kenkyū-buntansha)	OGA Noritaka 北海道大学, 歯学研究科, 助教 (40548202) 樋田京子北海道大学, 歯学研究科(研究院), その他 (40399952)
Project Period (FY)	2012-04-01 – 2015-03-31
Project Status	Completed (Fiscal Year 2014)
Budget Amount *help	¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000) Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000) Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Keywords	腫瘍血管内皮 / アラキドン酸カスケード / 腫瘍血管内皮細胞 / COX-2 / プロスタサイクリン / プロスタサイクリンレセプター / アラキドン酸 / 癌
Outline of Final Research Achievements	We found that COX-2/ prostaglandin E2 (PGE2) and prostacyclin (PGI2) was expressed highly in a tumor endothelial cells.In others to use expensive molecular target medicine for as a treatment strategy of the vascularization inhibition therapy, the COX-2/ prostaglandin E2 (PGE2) inhibitor could used cancer treatment.Targeting tumor angiogenesis is an established strategy for cancer therapy.